Human SOST/Sclerostin Quantikine ELISA Kit Summary
Background |
The Quantikine Human SOST immunoassay is a 4.5 hour solid-phase
ELISA designed to measure SOST in human cell culture supernates,
serum, and plasma. It contains NS0-expressed recombinant human SOST and
antibodies raised against the recombinant factor. This immunoassay has
been shown to accurately quantitate the recombinant human SOST. Results
obtained using natural human SOST showed... dose response curves
that were parallel to the standard curves obtained using the Quantikine
kit standards. These results indicate that this kit can be used to
determine relative mass values for natural SOST. |
Specificity |
Natural and recombinant human SOST |
Source |
N/A |
Assay Type |
Solid Phase Sandwich ELISA |
Inter-Assay |
|
Intra-Assay |
|
Spike Recovery |
|
Sample Volume |
|
Gene |
SOST |
Applications/Dilutions
Dilutions |
|
Application Notes |
No significant interference observed with available related molecules. |
Publications |
|
Packaging, Storage & Formulations
Storage |
Store the unopened product at 2 - 8 °C. Do not use past expiration date. |
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Human SOST/Sclerostin Quantikine ELISA Kit
Background
SOST, also known as Sclerostin, is a Cerberus/DAN family BMP antagonist and is an important regulator of bone homeostasis. Inactivating mutations in the SOST gene can cause sclerosteosis and van Buchem disease. SOST is expressed by terminally differentiated cells embedded in mineralized matrix including osteocytes, hypertrophic and prehypertrophic chondrocytes, and tooth cementocytes. Its expression is induced by BMP-2, -4, and -6 and is inhibited by parathyroid hormone (PTH). Its downregulation in osteocytes by physical loading of bone contributes to the mechanical sensor function of osteocytes and the subsequent increase in bone growth. SOST binds to BMP-2, -4, -5, -6, and -7 and inhibits the osteogenic differentiation induced by these BMPs. It inhibits canonical Wnt signaling by binding to LRP-5 and LRP-6 and inhibiting their association with Frizzled receptors. SOST reduces the proliferation of mesenchymal stem cells (MSC) and induces MSC apoptosis. Circulating levels of SOST are elevated in pathologies with bone involvement including low bone mineral density, Paget’s disease, multiple myeloma, and prostate cancer with bone metastases. It is also elevated in advanced chronic kidney disease, alcoholic liver disease, type 2 diabetes, and patients with increased abdominal and gynoid fat.
Customers Who Viewed This Item Also Viewed...
Species: Hu
Applications: IHC, WB
Species: Hu
Applications: BA
Species: Hu
Applications: IHC, IHC-P
Species: Mu
Applications: BA
Species: Hu
Applications: ELISA
Species: Mu
Applications: BA
Species: Hu, Rt
Applications: CyTOF-ready, ICC, IHC, ICFlow
Species: Ca, Hu, Mu, Po, Pm, Rt(-)
Applications: Dual ISH-IHC, ICC/IF, IHC, IHC-Fr, IHC-P, IP, KO, PLA, WB
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P
Species: Mu
Applications: IHC, WB
Species: Mu
Applications: IHC
Species: Hu
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ICC
Species: Hu
Applications: ELISA, ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ICC/IF, IHC, IHC-P
Species: Hu
Applications: BA
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
FAQs for SOST/Sclerostin (DSST00) (0)
Additional SOST/Sclerostin Products
Blogs on SOST/Sclerostin